Forterra Announces Definitive Agreement with Thompson Pipe Group
26.6.2017 14:00 | NASDAQ OMX
Thompson Pipe Group to Acquire Forterra's U.S. Concrete and Steel Pressure Pipe Assets
Forterra to Acquire Thompson Pipe's Drainage Pipe & Products Manufacturing Facility with a Strategic Position in Houston Market
IRVING, Texas, June 26, 2017 (GLOBE NEWSWIRE) -- Forterra, Inc. ("Forterra" or the "Company") (Nasdaq:FRTA), a leading manufacturer of water infrastructure pipe and products in the United States and Eastern Canada, today announced it has entered into a definitive agreement to sell the U.S. concrete and steel pressure pipe assets of its Water Pipe and Products business segment to Thompson Pipe Group. The transaction is subject to customary closing conditions and is expected to close in the third quarter of 2017.
Under the terms of the agreement, an affiliate of Thompson Pipe Group will acquire assets related to five Forterra manufacturing facilities and a fittings facility. Forterra will receive approximately $23.2 million in cash, exclusive of fees and expenses, as well as assets relating to a drainage pipe and products manufacturing facility located in Conroe, Texas, which primarily serves the Houston market. The Company intends to use the net proceeds from the transaction to pay down debt. The transaction is expected to be immediately accretive to the Company's earnings, margins and cash flows.
"After a review of strategic alternatives to enhance shareholder value, we are pleased to reach this agreement with Thompson Pipe Group," said Jeff Bradley, CEO of Forterra. "We believe this transaction, which includes not only the divestiture of non-core assets, but also the acquisition of a drainage pipe and products facility in the large Houston market, will enable us to sharpen our focus on our core business and high-margin growth opportunities and more efficiently allocate capital to execute our strategic objectives."
Key Transaction Rationale
· Expected to be immediately accretive to Forterra's earnings, margins and cash flows:
Eliminates significant working capital requirements associated with contracts with uncertain delivery schedules; and
Reduces expected maintenance capital expenditure requirements.
· Acquisition of Houston-area plant bolsters Forterra's strategic position in a large and growing market, and will become part of Forterra's Drainage Pipe and Products business segment.
· With the asset sale, Forterra will focus on its core drainage and ductile iron pipe product lines with favorable end-market fundamentals:
The Company's U.S. concrete and steel pressure pipe assets have minimal synergies with the remaining core business due to limited customer overlap, separate manufacturing facilities and a different manufacturing process.
· Exits a business with unfavorable market dynamics in the United States:
Long-term projects subject to customer delays can create earnings volatility; and
Narrow market segment with significant competition and limited near-term catalysts for improvement in demand.
The following is a summary of certain financial information for the U.S. Concrete and Steel Pressure Pipe assets to be sold in the transaction:
· For the year ended December 31, 2016, net sales were $99.7 million, net loss was $1.6 million and Adjusted EBITDA1 was $1.4 million
· For the quarter ended March 31, 2016 as compared to the quarter ended March 31, 2017, net sales declined from $30.0 million to $27.7 million, net income of $1.0 million declined to a net loss of $6.1 million and Adjusted EBITDA1 of $1.9 million declined to a loss of $5.5 million
Forterra, Inc. (Nasdaq:FRTA) is a leading manufacturer of water and drainage pipe and products in the U.S. and Eastern Canada for a variety of water-related infrastructure applications, including water transmission, distribution, drainage and stormwater management. Based in Irving, Texas, Forterra's product breadth and scale help make it a one-stop shop for water-related pipe and products, and a preferred supplier to a wide variety of customers, including contractors, distributors and municipalities. For more information on Forterra, visit forterrabp.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements may be identified by the use of words such as "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on historical information available at the time the statements are made and are based on management's reasonable belief or expectations with respect to future events, and are subject to risks and uncertainties, many of which are beyond the Company's control, that could cause actual performance or results to differ materially from the belief or expectations expressed in or suggested by the forward-looking statements. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update any forward-looking statement to reflect future events, developments or otherwise, except as may be required by applicable law. Investors are referred to the Company's filings with the Securities and Exchange Commission for additional information regarding the risks and uncertainties that may cause actual results to differ materially from those expressed in any forward-looking statement.
1 Adjusted EBITDA is a non-GAAP measure. See Appendix A for how we define this measure, a discussion of why we believe it is useful and reconciliation thereof to the most directly comparable GAAP financial measure.
Reconciliation of Non-GAAP Measure (Unaudited)
In addition to results calculated under generally accepted accounting principles in the United States ("GAAP"), in this press release we also present adjusted EBITDA. Adjusted EBITDA is a non-GAAP measure and has been presented in this press release as a supplemental measure of financial performance that is not required by, or presented in accordance with GAAP. We calculate adjusted EBITDA as net income (loss) before interest expense, income tax benefit (expense), depreciation and amortization and before impairment and restructuring charges, (gains)/losses on the sale of property, plant and equipment and certain other income and expenses, such as transaction costs, carve-out costs related to our separation from HeidelbergCement and costs associated with disposed sites.
Adjusted EBITDA is presented in this press release because it is an important metric used by management as one of the means by which it assesses our financial performance. Adjusted EBITDA is also frequently used by analysts, investors and other interested parties to evaluate companies in our industry. We use adjusted EBITDA as a supplement to GAAP measures of performance to evaluate the effectiveness of our business strategies, to make budgeting decisions, to allocate resources and to compare our performance relative to our peers. Adjusted EBITDA is also an important measure for assessing our operating results and evaluating operating performance on a consistent basis, by excluding the impacts of depreciation, amortization, income tax expense, interest expense and other items not indicative of ongoing operating performance. Additionally, this measure, when used in conjunction with related GAAP financial measures, provides investors with additional financial analytical framework which management uses, in addition to historical operating results, as the basis for financial, operational and planning decisions and present measurements that third parties have indicated are useful in assessing the Company and its results of operations.
Adjusted EBITDA has certain limitations. Adjusted EBITDA should not be considered as an alternative to net income or as a substitute for any other measure of financial performance calculated in accordance with GAAP. This measure also should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items for which these non-GAAP measures make adjustments. Adjusted EBITDA is not intended to be a liquidity measure because of certain limitations such as: (i) it does not reflect cash outlays for capital expenditures or future contractual commitments; (ii) it does not reflect changes in, or cash requirements for, working capital; (iii) it does not reflect interest expense, or the cash requirements necessary to service interest, or principal payments, on indebtedness; (iv) it does not reflect income tax expense or the tax necessary to pay income taxes; and (v) although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and this non-GAAP measure does not reflect cash requirements for such replacements.
Other companies, including other companies in our industry, may not use this measure or may calculate this measure differently than as presented in this press release, limiting its usefulness as a comparative measure. In evaluating adjusted EBITDA, you should be aware that in the future we will incur expenses that are the same as or similar to some of the adjustments made in the calculations below and the presentation of adjusted EBITDA should not be construed to mean that our future results will be unaffected by such adjustments. Management compensates for these limitations by using adjusted EBITDA as a supplemental financial metric and in conjunction with results prepared in accordance with GAAP.
|Forterra's U.S. Concrete and Steel Pressure Pipe Assets|
|Reconciliation of net income (loss) to adjusted EBITDA|
|($ in thousands)|
|Three months ended March 31,||Year ended December 31,|
|Net income (loss)||$||(6,071||)||$||956||$||(1,594||)|
|Depreciation and amortization||750||985||3,639|
|Income tax expense||-||-||1,828|
|(Gain) loss on sale of property, plant & equipment, net1||358||-||(129||)|
|Other (gains) expenses3||(538||)||-||(3,263||)|
|1 (Gain) loss on sale of property, plant and equipment, primarily related to the disposition of manufacturing facilities.|
|2 Non-cash equity compensation expense.|
|3 Other (gains) losses, such as gain on insurance proceeds related to the destruction of property.|
Executive Vice President, Chief Financial Officer
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Forterra, Inc. via Globenewswire
Följ NASDAQ OMX
Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.
Senaste nyheterna från NASDAQ OMX
Forterra Announces Second Quarter 2017 Earnings Schedule27.7.2017 22:30 | Pressmeddelande
IRVING, Texas, July 27, 2017 (GLOBE NEWSWIRE) -- Forterra, Inc. ("Forterra") (Nasdaq:FRTA) plans to release second quarter 2017 financial results before the market open on Thursday, August 10, 2017. A conference call to review financial results will also be held on Thursday, August 10, 2017 at 8:30 a.m. Eastern time (7:30 a.m. Central). Hosting the call will be Jeff Bradley, Chief Executive Officer, and Matt Brown, Executive Vice President and Chief Financial Officer. CONFERENCE CALL AND WEBCAST DETAILS Webcast Information Event: Q2 2017 Forterra, Inc. Earnings Call Date: Thursday, August 10, 2017 Time: 8:30 a.m. Eastern Time (7:30 a.m. Central) Webcast: http://edge.media-server.com/m/p/uxphuyzt Conference Call Information U.S.: 1-574-990-1396 Toll-Free: 1-844-498-0572 Parti
TGS Q2 2017 webcast and teleconference27.7.2017 18:14 | Pressmeddelande
ASKER, Norway, July 27, 2017 (GLOBE NEWSWIRE) -- TGS will release its Q2 2017 results at approximately 07:00 CEST on 3 August 2017. CEO Kristian Johansen and CFO Sven Børre Larsen will present the results at 09:00 CEST at the Hotel Continental, Stortingsgata 24/26 in Oslo, Norway. The presentation is open to the public and can be followed live on the internet at www.tgs.com. The slides from the presentation will also be available in PDF format at both the TGS and Oslo Stock Exchange websites. CEO Kristian Johansen and CFO Sven Børre Larsen will host a conference call on 3 August 2017 at 15:00 CEST (09:00 EDT). Attendees may want to call 5-10 minutes before to ensure registration and access. Norwegian attendees are invited to call + 800 51084 or + 47 2100 2610 International attendees are invited to call 0800 358 6377 or + 44 (0)330 336 9105 US attendees are invited to call +1 866-
Vistajet Launches New Digital Platforms as Growth Accelerates in China27.7.2017 14:36 | Pressmeddelande
VistaJet grows team and launches Chinese website owing to passenger demand VistaJet VistaJet Challenger 850 VistaJet Ltd For the six months to 30th June 2017: Program Membership sales increase globally by a record 57% as customer retention hits 91% across all regions 12% year-on-year increase on passenger departures from China 100% customer renewal rate in Greater China in the first half of 2017 VistaJet Chinese website launched at www.vistajet.cn HONG KONG, July 27, 2017 (GLOBE NEWSWIRE) -- VistaJet continues to build on its China growth and demonstrates a commitment to the region by expanding its team and launching
Minerva Neurosciences to Report Second Quarter 2017 Financial Results and Business Updates on August 3, 201727.7.2017 14:30 | Pressmeddelande
Management to host conference call WALTHAM, Mass., July 27, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the second quarter of 2017 on Thursday, August 3, 2017. The Company will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss these results and updates. The live call may be accessed by dialing (877) 312-5845 for domestic callers or (765) 507-2618 for international callers and referring to conference ID number 53086270. A live webcast of the conference call will be available online in the Investors and Media section of the Company's website at ir.minervaneurosciences.com. The archived webcast will be available on the Company's website beginning approximately two hours after
Vertiv Sells ASCO® to Schneider Electric27.7.2017 14:22 | Pressmeddelande
Sale enables greater focus on core business COLUMBUS, Ohio, July 27, 2017 (GLOBE NEWSWIRE) -- Vertiv, formerly Emerson Network Power, today announced plans to sell its ASCO® business as it continues to sharpen its focus on the digital critical infrastructure space. The $1.25 billion sale to Schneider Electric allows Vertiv to apply additional resources toward business and technological advancements in its core data center, telecommunications and commercial and industrial markets. As Vertiv has repositioned itself after being sold to Platinum Equity in November 2016, it became clear that ASCO's strengths in the automatic transfer switch arena fell outside the new organization's more focused strategy, said Vertiv CEO Rob Johnson. "This sale is a significant step forward in our evolution as the premier provider of digital critical infrastructure solutions," Johnson said. "This is consistent with our strategy of focus
TESARO and Takeda Enter Into Exclusive Licensing Agreement to Develop and Commercialize Novel Cancer Therapy Niraparib in Japan27.7.2017 13:00 | Pressmeddelande
- Takeda's Rights Include all Potential Indications for Niraparib in Japan and Rights Excluding Prostate Cancer in South Korea, Taiwan, Russia and Australia - TESARO to Receive $100 Million Upfront Payment and is Eligible for Future Regulatory and Commercial Milestones, Plus Royalties WALTHAM, Mass. and OSAKA, Japan, July 27, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced an exclusive licensing agreement for the commercialization and clinical development of niraparib, a novel poly ADP-ribose polymerase (PARP) inhibitor. This agreement includes the development of niraparib for the treatment of all tumor types in Japan, and all tumor types excluding prostate cancer in South Korea, Taiwan, Russia and Australia. Niraparib, first marketed in the U.S. in April under the brand name ZEJULA(TM), has quickly
I vårt nyhetsrum kan du läsa de senaste nyheterna, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt nyhetsrum